AMRXAmneal Pharmaceuticals, Inc.
Pharmaceutical Preparations
- Revenue
- $3.0B
- 8.0% YoY
- Operating margin
- 13.1%
- 46% YoY
- EBITDA
- $451M
- 45% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 5.6×
- $2.5B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear472% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear16% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $2.1B | $2.2B | $2.4B | $2.8B | $3.0B | 8.0% |
| Operating income | $153M | −$95M | $204M | $249M | $394M | 58% |
| Net income | $13M | −$271M | −$84M | −$117M | $72M | 162% |
| Operating cash flow | $242M | $65M | $346M | $295M | $340M | 15% |
| Capex | $48M | $46M | $43M | $52M | $70M | 35% |
| Stock-based comp | $28M | $32M | $27M | $28M | $32M | 15% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.